Source updated November 5, 2026: UC San Diego clinical-trial listing for NCT07592169, checked against the current ClinicalTrials.gov record and its November 10 recruitment update.

A larger test of gamma EEG feedback UC San Diego has opened recruitment for a Phase 2 trial asking whether gamma EEG neurofeedback can improve working memory in adults with schizophrenia or schizoaffective disorder. The study plans to enroll 104 adults ages 18 to 55 at one San Diego site. No participant results are available.

The active group will receive real-time feedback based on frontal gamma coherence recorded at F3 and F4 in the 30 to 50 hertz range. The comparison group will complete the same session structure but receive prerecorded feedback that is unrelated to its own EEG. Participants and outcome assessors are blinded to group assignment.

Why the sham comparison matters Neurofeedback research can be affected by expectations, repeated practice, attention from study staff and learning from the task itself. A closely matched sham condition helps separate those effects from the contribution of contingent EEG feedback. It does not eliminate every source of bias, but it is a stronger test than an uncontrolled training series.

What the study will measure Both groups are scheduled for 30 sessions across 12 weeks. The main questions focus on working-memory performance and frontal gamma coherence from baseline to week 12. The protocol also measures global cognition, symptoms, negative symptoms, independent living skills and community functioning. Follow-up visits at three and six months are intended to show whether any observed changes persist beyond training.

The evidence boundary The listing describes a rigorous plan, not evidence that gamma neurofeedback works for schizophrenia. Estimated enrollment, completion in 2030 and all outcome time points may change. A change in gamma coherence would not by itself prove better memory or everyday functioning, and favorable pilot findings do not guarantee confirmation in a larger trial.

Future reporting should show enrollment and attrition, protocol adherence, masking performance, adverse events, between-group estimates with uncertainty, correction for multiple outcomes and whether any cognitive change is meaningful in daily life. The device and electrode details document the planned protocol; they do not establish commercial superiority.

For prospective participants The UC San Diego listing identifies one recruiting location and detailed eligibility criteria. A trial listing does not mean the intervention is known to be safe or effective, and joining a study is not the same as receiving established care. Questions about eligibility, medication stability, study visits, risks and alternatives belong with the study team and the person's treating clinicians.

Disclosure This is coverage of a recruiting clinical trial, not a treatment recommendation or efficacy report. Prepared with AI assistance; the UC San Diego listing and NCT07592169 record were checked November 17, 2026. The image is an AI-generated conceptual illustration with a fictional person. It does not depict a participant, device, EEG result or clinical outcome.